English

ACTINIUM PHARMACEUTICALS, INC.

EDGAR

ATNM Current report (8-K) · filed 2026-10-15

Annual consolidated revenue for 2025: about USD 90K, using the latest reported figures. The previous period, 2023, was about USD 81K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

35 million uref_1687216566

2026 Q2 · uref_1687216566

Exact inputs and evidence

Revenue: 35000000 uref_1687216566 Source

Operating margin

78.76%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 27565000 uref_1687216566 Source
Revenue: 35000000 uref_1687216566 Source

Cash and cash equivalents: 36.5 million uref_1687216566 2026-06-30 Source
Exact value

36473000 uref_1687216566
Long-term debt including current maturities: Not available
Shares outstanding: 31.4 million uref_988064053 2026-06-30 Source
Exact value

31441436 uref_988064053

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-22.9 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -12966000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7574000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -19291000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12966000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -24580000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -19291000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5870000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-15.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 4.36 million

Prior period

−USD 38.24 million

2024-01-01 – 2024-12-31
Current period

−USD 33.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-33887000 − -38243000 = 4356000 USD

-38243000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-33887000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Year-over-year change in Net income: 4356000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -33887000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#1046522 Filing: 000121390026036504 Input fundies:NetIncome: -38243000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#1046823 Filing: 000121390026036504
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 8.49 million

Prior period

−USD 33.07 million

2024-01-01 – 2024-12-31
Current period

−USD 24.58 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-24580000 − -33072000 = 8492000 USD

-33072000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-24580000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Year-over-year change in Operating cash flow: 8492000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -24580000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828288 Filing: 000121390026036504 Input fundies:OperatingCashFlow: -33072000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828744 Filing: 000121390026036504
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+845.5%

Prior period

USD 11,000

2024-01-01 – 2024-12-31
Current period

USD 104,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

104000 − 11000 = 93000 USD

11000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
104000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Year-over-year change in Capital expenditure: 93000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 104000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830200 Filing: 000121390026036504 Input fundies:CapitalExpenditure: 11000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830644 Filing: 000121390026036504
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 90,000 100% of revenue
Operating costs Derived USD 36.34 million 40,374% of revenue
Operating income −USD 36.25 million −40,274% of revenue
Tax, interest and other Derived −USD 2.36 million −2,622% of revenue
Net income −USD 33.89 million −37,652% of revenue

Cash

Operating cash flow −USD 24.58 million −27,311% of revenue
Capital expenditure USD 104,000 116% of revenue
Free cash flow Derived −USD 24.68 million −27,427% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 2,282% of revenue.
2022 Operating loss: operating costs were 3,411% of revenue.
2023 Operating loss: operating costs were 64,199% of revenue.
2025 Operating loss: operating costs were 40,374% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	1144000	26108000 Derived	-24964000	-190000 Derived	-24774000	-20999000 Derived	Source 2021-01-01 – 2021-12-31: 1144000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -24964000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -24774000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -20866000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 133000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1030000	35134000 Derived	-34104000	-1087000 Derived	-33017000	8278000 Derived	Source 2022-01-01 – 2022-12-31: 1030000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -34104000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -33017000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 8644000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 366000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	81000	52001000 Derived	-51920000	-3102000 Derived	-48818000	-47488000 Derived	Source 2023-01-01 – 2023-12-31: 81000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -51920000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -48818000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -47335000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 153000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	90000	36337000 Derived	-36247000	-2360000 Derived	-33887000	-24684000 Derived	Source 2025-01-01 – 2025-12-31: 90000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -36247000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -33887000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -24580000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 104000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 90K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	1144000	Revenue: 1144000 Open source
20222022-12-31	Revenue	1030000	Revenue: 1030000 Open source
20232023-12-31	Revenue	81000	Revenue: 81000 Open source
20252025-12-31	Revenue	90000	Revenue: 90000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-92.1% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 1144000 Open source
20222022-12-31	Year over year	-10%	Revenue: 1030000 Open source Revenue: 1144000 Open source
20232023-12-31	Year over year	-92.1%	Revenue: 81000 Open source Revenue: 1030000 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 90000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -40,274.4% 2025

Net margin -37,652.2% 2025

Free cash flow margin -27,426.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-2,182.2%	Operating Income: -24964000 Open source Revenue: 1144000 Open source
20222022-12-31	Operating margin	-3,311.1%	Operating Income: -34104000 Open source Revenue: 1030000 Open source
20232023-12-31	Operating margin	-64,098.8%	Operating Income: -51920000 Open source Revenue: 81000 Open source
20252025-12-31	Operating margin	-40,274.4%	Operating Income: -36247000 Open source Revenue: 90000 Open source
20212021-12-31	Net margin	-2,165.6%	Net Income: -24774000 Open source Revenue: 1144000 Open source
20222022-12-31	Net margin	-3,205.5%	Net Income: -33017000 Open source Revenue: 1030000 Open source
20232023-12-31	Net margin	-60,269.1%	Net Income: -48818000 Open source Revenue: 81000 Open source
20252025-12-31	Net margin	-37,652.2%	Net Income: -33887000 Open source Revenue: 90000 Open source
20212021-12-31	Free cash flow margin	-1,835.6%	Revenue: 1144000 Open source Operating Cash Flow: -20866000 Open source Capital Expenditure: 133000 Open source
20222022-12-31	Free cash flow margin	803.7%	Revenue: 1030000 Open source Operating Cash Flow: 8644000 Open source Capital Expenditure: 366000 Open source
20232023-12-31	Free cash flow margin	-58,627.2%	Revenue: 81000 Open source Operating Cash Flow: -47335000 Open source Capital Expenditure: 153000 Open source
20252025-12-31	Free cash flow margin	-27,426.7%	Revenue: 90000 Open source Operating Cash Flow: -24580000 Open source Capital Expenditure: 104000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -24.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-20866000	Operating Cash Flow: -20866000 Open source
20222022-12-31	Operating cash flow	8644000	Operating Cash Flow: 8644000 Open source
20232023-12-31	Operating cash flow	-47335000	Operating Cash Flow: -47335000 Open source
20252025-12-31	Operating cash flow	-24580000	Operating Cash Flow: -24580000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -24.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-20999000	Operating Cash Flow: -20866000 Open source Capital Expenditure: 133000 Open source
20222022-12-31	Free cash flow	8278000	Operating Cash Flow: 8644000 Open source Capital Expenditure: 366000 Open source
20232023-12-31	Free cash flow	-47488000	Operating Cash Flow: -47335000 Open source Capital Expenditure: 153000 Open source
20252025-12-31	Free cash flow	-24684000	Operating Cash Flow: -24580000 Open source Capital Expenditure: 104000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Liabilities / assets	Not reported	No source recorded
2022-12-31	Liabilities / assets	Not reported	No source recorded
2023-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Current assets / current liabilities	Not reported	No source recorded
2022-12-31	Current assets / current liabilities	Not reported	No source recorded
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 24.32 million Exact value Exact value: -24321724 USD 2016-01-01 – 2016-12-31: -24321724 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2016-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -24321724 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24321724 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#179844 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	−USD 20.79 million Exact value Exact value: -20789237 USD 2016-01-01 – 2016-12-31: -20789237 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2016-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -20789237 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20789237 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#184741 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	USD 59,960 Exact value Exact value: 59960 USD 2016-01-01 – 2016-12-31: 59960 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2016-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 59960 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 59960 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#186034 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	−USD 20.85 million Calculation and evidence -20789237 − 59960 USD Exact free cash flow: -20849197 USD 2016-01-01 – 2016-12-31: -20789237 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 59960 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2016-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -20849197 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20789237 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#184741 Filing: 000121390019004269 Input fundies:CapitalExpenditure: 59960 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#186034 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 26.6 million Exact value Exact value: -26601235 USD 2017-01-01 – 2017-12-31: -26601235 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2017-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -26601235 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26601235 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#179686 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	−USD 21.55 million Exact value Exact value: -21553346 USD 2017-01-01 – 2017-12-31: -21553346 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2017-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -21553346 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21553346 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#184525 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	USD 24,739 Exact value Exact value: 24739 USD 2017-01-01 – 2017-12-31: 24739 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2017-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 24739 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24739 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#185822 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.	−USD 21.58 million Calculation and evidence -21553346 − 24739 USD Exact free cash flow: -21578085 USD 2017-01-01 – 2017-12-31: -21553346 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 24739 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2017-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -21578085 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21553346 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#184525 Filing: 000121390019004269 Input fundies:CapitalExpenditure: 24739 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/atnm-20181231.xml#185822 Filing: 000121390019004269 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 23.65 million Exact value Exact value: -23653963 USD 2018-01-01 – 2018-12-31: -23653963 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2018-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -23653963 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23653963 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/atnm-20191231.xml#97360 Filing: 000121390020011475 The citation records this snapshot. The page link may show a newer release later.	−USD 20.57 million Exact value Exact value: -20571056 USD 2018-01-01 – 2018-12-31: -20571056 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2018-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -20571056 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20571056 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/atnm-20191231.xml#101150 Filing: 000121390020011475 The citation records this snapshot. The page link may show a newer release later.	USD 96,092 Exact value Exact value: 96092 USD 2018-01-01 – 2018-12-31: 96092 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2018-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 96092 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 96092 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/atnm-20191231.xml#101552 Filing: 000121390020011475 The citation records this snapshot. The page link may show a newer release later.	−USD 20.67 million Calculation and evidence -20571056 − 96092 USD Exact free cash flow: -20667148 USD 2018-01-01 – 2018-12-31: -20571056 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 96092 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2018-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -20667148 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20571056 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/atnm-20191231.xml#101150 Filing: 000121390020011475 Input fundies:CapitalExpenditure: 96092 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/atnm-20191231.xml#101552 Filing: 000121390020011475 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 21.9 million Exact value Exact value: -21900000 USD 2019-01-01 – 2019-12-31: -21900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2019-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -21900000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/atnm-20201231.xml#55121 Filing: 000121390021019297 The citation records this snapshot. The page link may show a newer release later.	−USD 21.46 million Exact value Exact value: -21462000 USD 2019-01-01 – 2019-12-31: -21462000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2019-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -21462000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/atnm-20201231.xml#69717 Filing: 000121390021019297 The citation records this snapshot. The page link may show a newer release later.	USD 64,000 Exact value Exact value: 64000 USD 2019-01-01 – 2019-12-31: 64000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2019-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 64000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 64000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/atnm-20201231.xml#70084 Filing: 000121390021019297 The citation records this snapshot. The page link may show a newer release later.	−USD 21.53 million Calculation and evidence -21462000 − 64000 USD Exact free cash flow: -21526000 USD 2019-01-01 – 2019-12-31: -21462000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 64000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2019-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -21526000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/atnm-20201231.xml#69717 Filing: 000121390021019297 Input fundies:CapitalExpenditure: 64000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/atnm-20201231.xml#70084 Filing: 000121390021019297 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 22.22 million Exact value Exact value: -22215000 USD 2020-01-01 – 2020-12-31: -22215000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2020-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -22215000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22215000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390022015208/f10k2021_actiniumpharma.htm#572133 Filing: 000121390022015208 The citation records this snapshot. The page link may show a newer release later.	−USD 21.62 million Exact value Exact value: -21617000 USD 2020-01-01 – 2020-12-31: -21617000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2020-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -21617000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21617000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390022015208/f10k2021_actiniumpharma.htm#596005 Filing: 000121390022015208 The citation records this snapshot. The page link may show a newer release later.	USD 253,000 Exact value Exact value: 253000 USD 2020-01-01 – 2020-12-31: 253000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2020-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 253000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 253000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390022015208/f10k2021_actiniumpharma.htm#597943 Filing: 000121390022015208 The citation records this snapshot. The page link may show a newer release later.	−USD 21.87 million Calculation and evidence -21617000 − 253000 USD Exact free cash flow: -21870000 USD 2020-01-01 – 2020-12-31: -21617000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 253000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2020-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -21870000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21617000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390022015208/f10k2021_actiniumpharma.htm#596005 Filing: 000121390022015208 Input fundies:CapitalExpenditure: 253000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390022015208/f10k2021_actiniumpharma.htm#597943 Filing: 000121390022015208 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 24.77 million Exact value Exact value: -24774000 USD 2021-01-01 – 2021-12-31: -24774000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2021-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -24774000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24774000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390023025597/f10k2022_actiniumph.htm#625976 Filing: 000121390023025597 The citation records this snapshot. The page link may show a newer release later.	−USD 20.87 million Exact value Exact value: -20866000 USD 2021-01-01 – 2021-12-31: -20866000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2021-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -20866000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20866000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390023025597/f10k2022_actiniumph.htm#633562 Filing: 000121390023025597 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2021-01-01 – 2021-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2021-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390023025597/f10k2022_actiniumph.htm#635379 Filing: 000121390023025597 The citation records this snapshot. The page link may show a newer release later.	−USD 21 million Calculation and evidence -20866000 − 133000 USD Exact free cash flow: -20999000 USD 2021-01-01 – 2021-12-31: -20866000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2021-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -20999000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20866000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390023025597/f10k2022_actiniumph.htm#633562 Filing: 000121390023025597 Input fundies:CapitalExpenditure: 133000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390023025597/f10k2022_actiniumph.htm#635379 Filing: 000121390023025597 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 33.02 million Exact value Exact value: -33017000 USD 2022-01-01 – 2022-12-31: -33017000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2022-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -33017000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33017000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023_actinium.htm#706157 Filing: 000121390024028038 The citation records this snapshot. The page link may show a newer release later.	USD 8.64 million Exact value Exact value: 8644000 USD 2022-01-01 – 2022-12-31: 8644000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2022-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: 8644000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8644000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023_actinium.htm#714721 Filing: 000121390024028038 The citation records this snapshot. The page link may show a newer release later.	USD 366,000 Exact value Exact value: 366000 USD 2022-01-01 – 2022-12-31: 366000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2022-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 366000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 366000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023_actinium.htm#716721 Filing: 000121390024028038 The citation records this snapshot. The page link may show a newer release later.	USD 8.28 million Calculation and evidence 8644000 − 366000 USD Exact free cash flow: 8278000 USD 2022-01-01 – 2022-12-31: 8644000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 366000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2022-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: 8278000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8644000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023_actinium.htm#714721 Filing: 000121390024028038 Input fundies:CapitalExpenditure: 366000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023_actinium.htm#716721 Filing: 000121390024028038 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 48.82 million Exact value Exact value: -48818000 USD 2023-01-01 – 2023-12-31: -48818000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2023-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -48818000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48818000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm#795475 Filing: 000121390025026371 The citation records this snapshot. The page link may show a newer release later.	−USD 47.34 million Exact value Exact value: -47335000 USD 2023-01-01 – 2023-12-31: -47335000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2023-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -47335000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47335000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm#803599 Filing: 000121390025026371 The citation records this snapshot. The page link may show a newer release later.	USD 153,000 Exact value Exact value: 153000 USD 2023-01-01 – 2023-12-31: 153000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2023-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 153000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 153000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm#805615 Filing: 000121390025026371 The citation records this snapshot. The page link may show a newer release later.	−USD 47.49 million Calculation and evidence -47335000 − 153000 USD Exact free cash flow: -47488000 USD 2023-01-01 – 2023-12-31: -47335000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 153000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2023-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -47488000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47335000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm#803599 Filing: 000121390025026371 Input fundies:CapitalExpenditure: 153000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm#805615 Filing: 000121390025026371 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 38.24 million Exact value Exact value: -38243000 USD 2024-01-01 – 2024-12-31: -38243000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2024-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -38243000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38243000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#1046823 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	−USD 33.07 million Exact value Exact value: -33072000 USD 2024-01-01 – 2024-12-31: -33072000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2024-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -33072000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33072000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828744 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2024-01-01 – 2024-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2024-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830644 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	−USD 33.08 million Calculation and evidence -33072000 − 11000 USD Exact free cash flow: -33083000 USD 2024-01-01 – 2024-12-31: -33072000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2024-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -33083000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33072000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828744 Filing: 000121390026036504 Input fundies:CapitalExpenditure: 11000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830644 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 33.89 million Exact value Exact value: -33887000 USD 2025-01-01 – 2025-12-31: -33887000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Net Income: -33887000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33887000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#1046522 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	−USD 24.58 million Exact value Exact value: -24580000 USD 2025-01-01 – 2025-12-31: -24580000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Operating Cash Flow: -24580000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24580000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828288 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	USD 104,000 Exact value Exact value: 104000 USD 2025-01-01 – 2025-12-31: 104000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Capital Expenditure: 104000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 104000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830200 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.	−USD 24.68 million Calculation and evidence -24580000 − 104000 USD Exact free cash flow: -24684000 USD 2025-01-01 – 2025-12-31: -24580000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 104000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACTINIUM PHARMACEUTICALS, INC. · 2025-12-31 ACTINIUM PHARMACEUTICALS, INC. (edgar:1388320) Free cash flow: -24684000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:10:14Z Snapshot: a724acd4d3624fb497c900a197880c22865bbf70d65bd484f75c477106493f92 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1388320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24580000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#828288 Filing: 000121390026036504 Input fundies:CapitalExpenditure: 104000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm#830200 Filing: 000121390026036504 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

141 filings · 3,377 latest values · 3,377 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001388320, 1388320, ATNM, atnm, edgar:1388320

Also known as ACTINIUM PHARMACEUTICALS, INC., Actinium Pharmaceuticals, Inc., CACTUS VENTURES, INC., Cactus Ventures, Inc.

ACTINIUM PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Trailing twelve months

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation